Ribi ImmunoChem, SmithKline Beecham Biologicals deal

SmithKline received a non-exclusive, worldwide license to use RIBI adjuvants in its cancer vaccines. RIBI will receive an annual license fee and milestone payments for each SmithKline vaccine incorpor...